Data from two Phase I/II trials presented at American Society of Hematology Annual Meeting on efficacy and safety profile of acalabrutinib as monotherapy and combination treatment1,2
Findings highlight overall response rates and emerging safety profile of acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor